Oxaliplatin: A new agent for colorectal cancer

摘要: For nearly 40 years, the medical treatment of colorectal cancer had been limited to fluoropyrimidines until recent development irinotecan (CPT-11). In past decade, a new agent has appeared, oxaliplatin. This third-generation platinum compound synergistic activity with 5-fluorouracil and is non-cross-resistant 5-fluorouracil, CPT-11, other agents. Numerous clinical trials in Europe have demonstrated oxaliplatin patients untreated refractory metastatic cancer. Nevertheless, US Food Drug Administration recently denied approval for as first-line because lack clear-cut survival advantage trials. Additional are ongoing United States will test adjuvant setting. These studies define role what appears be very useful important agent.